Potential Barriers to HPV Vaccine Provision Among Medical Practices in an Area with High Rates of Cervical Cancer

Journal of Adolescent Health

Volumn 43, Issue 4 SUPPL., 2008, Pages

  Keating, Katie M ^a   Brewer, Noel T ^a   Gottlieb, Sami L ^b   Liddon, Nicole ^b   Ludema, Christina ^a   Smith, Jennifer S ^a  

^a IL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adolescent health; Cervical cancer; HPV; Sexually transmitted infections; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG COST; FEMALE; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH INSURANCE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; PRIORITY JOURNAL; REIMBURSEMENT; RURAL AREA; SCHOOL CHILD; TELEPHONE; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; ATTITUDE OF HEALTH PERSONNEL; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; NORTH CAROLINA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PARENTS; PATIENT ACCEPTANCE OF HEALTH CARE; PHYSICIAN'S PRACTICE PATTERNS; RURAL HEALTH SERVICES; UTERINE CERVICAL NEOPLASMS;

EID: 52049114685     PISSN: 1054139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jadohealth.2008.06.015     Document Type: Article

References (17)

1. Harper D.M., Franco E.L., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
2. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
3. Munoz N., Bosch F.X., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 6 (2003) 518-527
4. Smith J.S., Lindsay L., Hoots B., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121 3 (2007) 621-632
5. Markowitz L.E., Dunne E.F., Saraiya M., et al. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). Morb Mortal Wkly Rep 56 RR-2 (2007) 1-24
6. Middleman A.B. Adolescent immunizations: policies to provide a shot in the arm for adolescents. J Adolesc Health 41 2 (2007) 109-118
7. Kempe A., Daley M.F., Parashar U.D., et al. Will pediatricians adopt the new rotavirus vaccine?. Pediatrics 119 1 (2007) 1-10
8. McInerny T.K., Cull W.L., and Yudkowsky B.K. Physician reimbursement levels and adherence to American Academy of Pediatrics well-visit and immunization recommendations. Pediatrics 115 4 (2005) 833-838
9. Kahn J.A., Rosenthal S.L., Tissot A.M., et al. Factors influencing pediatricians' intention to recommend human papillomavirus vaccines. Ambul Pediatr 7 5 (2007) 367-373
10. Kahn J.A., Zimet G.D., Bernstein D.I., et al. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health 37 (2005) 502-510
11. Davis M.M., Ndiaye S.M., Freed G.L., et al. Influence of insurance status and vaccine cost on physicians' administration of pneumococcal conjugate vaccine. Pediatrics 112 3 Pt 1 (2003) 521-526
12. Dempsey A.F., and Davis M.M. Overcoming barriers to adherence to HPV vaccination recommendations. Am J Managed Care 12 17 Suppl (2005) S484-S491
13. Brewer N.T., and Fazekas K.I. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 45 2-3 (2007) 107-114
14. Brewer N.T., Cuite C.L., Herrington J.E., and Weinstein N.D. Risk compensation and vaccination: can getting vaccinated cause people to engage in risky behaviors?. Ann Behav Med 34 1 (2007) 95-99
15. Zimet G.D., Liddon N., Rosenthal S.L., et al. Psychosocial aspects of vaccine acceptability. Vaccine 24 Suppl 3 (2006) S201-S209
16. North Carolina State Center for Health Statistics. Ten year cervical cancer incidence and mortality for the state of North Carolina by county. 2006. Unpublished data.
17. Ries LAG, Melbert D, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER Web site, 2007.